Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin

Science in China, Series C: Life Sciences

Volumn 50, Issue 4, 2007, Pages 447-456

  Miao, QingFang ^a   Shang, BoYang ^a   Ouyang, ZhiGang ^a   Liu, XiaoYun ^a   Zhen, YongSu ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Antibody based drugs; Fusion protein; Lidamycin; Single domain antibody; Type IV collagenase

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC C 1027; ANTINEOPLASTIC ANTIBIOTIC; CANCER ANTIBODY; COLLAGENASE; ENEDIYNE; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL; ARTICLE; BIOSYNTHESIS; CHICK EMBRYO; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; LIVER TUMOR; MOLECULAR WEIGHT; MOUSE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PLASMID; PROTEIN ENGINEERING; TUMOR CELL LINE;

AMINOGLYCOSIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, NEOPLASM; BASE SEQUENCE; CELL LINE, TUMOR; CHICK EMBRYO; COLLAGENASES; ENEDIYNES; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MOLECULAR WEIGHT; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMIDS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS;

MUS;

EID: 34547172637     PISSN: 10069305     EISSN: 18622798     Source Type: Journal    
DOI: 10.1007/s11427-007-0058-5     Document Type: Article

References (28)

1. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer, 2002, 98(3): 456-462
2. Holliger P, Hudson P J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol, 2005, 23: 1126-1136
3. Schlereth B, Fichtner I, Lorenczewski G, et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res, 2005, 65(7): 2882-2889
4. Haas C, Lulei M, Fournier P, et al. T-cell triggering by CD3-and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine, 2005, 23(19): 2439-2453
5. Fang M, Jiang X, Yang Z, et al. Effects of interlinker sequences on the biological properties of bispecific single-chain antibodies. Chin Sci Bull (in Chinese), 2003, 48(18): 1912-1918
6. Bang S, Nagata S, Onda M, et al. HA22 (R490A) is a recombinant immunotoxin with increased antitum or activity without an increase in animal toxicity. Clin Cancer Res, 2005, 11(4): 1545-1550
7. Sharma S K, Pedley R B, Bhatia J, et al. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res, 2005, 11: 814-825
8. Ward E S, Gussow W, Griffiths A D, et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature, 1989, 341: 544-546
9. Saerens D, Kinne J, Bosmans E, et al. Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem, 2004, 279(50): 51965-51972
10. Cortez-Retamozo V, Backmann N, Senter P D, et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res, 2004, 64(8): 2853-2857
11. Hu J L, Xue Y C, Xie M Y, et al. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo), 1988, 41: 1575-1579
12. Zhen Y S, Ming X Y, Yu B. A new macromolecular antitumor antibiotic, C-1027 III. Antitumor activity. J Antibiot, 1989, 42: 1294-1298
13. Xu Y J, Li D D, Zhen Y S. Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells. Cancer Chemother Pharmacol, 1990, 27: 41-46
14. Huang Y H, Shang B Y, Zhen Y S. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. World J Gastroenterol, 2005, 11: 3980-3984
15. Wang F Q, Shang B Y, Zhen Y S. Antitumor effects of molecule-downsized imunoconjugate composed of lidamycin and Fab'fragment of monoclonal antibody directed against type IV collagenase. Sci China Ser C-Life Sci, 2004, 47(1): 66-73
16. Li L, Huang Y H, Li Y, et al. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma. World J Gastroenterol, 2005, 11: 4478-4483
17. Wang F Q, Shang B Y, Zhen Y S. Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11. Acta Pharm Sin (in Chinese), 2003, 38(7): 515-519
18. Tanaka T, Fukuda-Ishisaka S, Hirama M, et al. Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J Mol Biol, 2001, 309: 267-283
19. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie, 2005, 87: 287-297
20. Tsumoto K, Shinoki K, Kondo H, et al. Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent - Application to a human single-chain Fv fragment. J Immunol Methods, 1998, 219: 119-129
21. Brinkmann U, Lee B K, Pastan I. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin. J Immunol, 1993, 150(7): 2774-82
22. Dubnovitsky A P, Kravchuk Z I, Chumanevich A A, et al. Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. Biochemistry, 2000, 65(9): 1011-1018
23. Martsev S P, Tsybovsky Y I, Stremovskiy O A, et al. Fusion of the antiferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability. Protein Eng Des Sel, 2004, 17: 85-93
24. Coulon S, Pellequer J L, Blachere T, et al. Functional characterization of an anti-estradiol antibody by site-directed mutagenesis and molecular modeling: Modulation of binding properties and prominent role of the VL domain in estradiol recognition. J Mol Recognit, 2002, 15: 6-18
25. Beucken T, Neer M, Sablon E, et al. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J Mol Biol, 2001, 310: 591-601
26. Wang J L, Zheng Y L, Wang B L, et al. Construction and activity analysis of a recombinant immunotoxin composed of PE38 and a disulfide stable single-chain antibody. Chin J Cell Mol Immun (in Chinese), 2006, 22(1): 74-77
27. Pastan I, Hassan R, Fitzgerald D J, et al. Immunotoxin therapy of cancer. Nat Rev Cancer, 2006, 6(7): 559-565
28. Trail P A, King H D, Dubowchik G M. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother, 2003, 52(5): 328-337